@article{TCR21115,
author = {Gustavo Werutsky and Tomás Reinert and André Poisl Fay},
title = {Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer},
journal = {Translational Cancer Research},
volume = {7},
number = {Suppl 5},
year = {2018},
keywords = {},
abstract = {The ALTERNATIVE trial has shown progression-free survival (PFS) benefit with the addition of lapatinib (LAP) to trastuzumab (TRAS) and an aromatase inhibitor (AI) among postmenopausal patients with hormone receptor (HR), human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (MBC). These findings were reported by Johnston et al. in the Journal of Clinical Oncology (1).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/21115}
}